"Extensive attempts to elicit HIV-1 resistance to hT5Cyp were unsuccessful. ...
"Upon challenge with HIV-1, these mice showed decreased viremia and productive infection in lymphoid organs and preserved numbers of human CD4+ T cells. We conclude that hT5Cyp is an extraordinarily robust inhibitor of HIV-1 replication and a promising anti–HIV-1 gene therapy candidate."
Read more in Journal of Clinical Investigation, September 8, 2009.
0 comments:
Post a Comment